Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.70 |
| ▸ | GSR | P00390 | 2/20 | 0.58 |
| ▸ | GRM8 | O00222 | 1/20 | 0.58 |
| ▸ | GRM6 | O15303 | 1/20 | 0.58 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.58 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.58 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.58 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.58 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.58 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.58 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.58 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.58 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142983 | 1.00 | SLC1A1 (0.70) | SLC1A1GSRGRM8GRM6GRIN2D | |
| SCHEMBL1666146 | 1.00 | SLC1A1 (0.70) | SLC1A1GSRGRM8GRM6GRIN2D | |
| Hydrochloric Acid SCHEMBL19520881 | 0.98 | SLC1A1 (0.68) | SLC1A1GSRGRM8GRM6GRIN2D | |
| SCHEMBL28377520 | 0.98 | SLC1A1 (0.68) | SLC1A1GSRGRM8GRM6GRIN2D | |
| Ammonia Solution, Strong SCHEMBL27721206 | 0.98 | SLC1A1 (0.68) | SLC1A1GSRGRM8GRM6GRIN2D | |
| SCHEMBL28160356 | 0.98 | SLC1A1 (0.68) | SLC1A1GSRGRM8GRM6GRIN2D | |
| Hydrochloric Acid SCHEMBL10516366 | 0.98 | SLC1A1 (0.68) | SLC1A1GSRGRM8GRM6GRIN2D | |
| SCHEMBL16343347 | 0.91 | SLC1A1 (0.60) | SLC1A1GSRGRM8GRM6GRIN2D | |
| Leucine SCHEMBL8642033 | 0.89 | SLC1A1 (0.68) | SLC1A1GSRGRM8GRM6GRIN2D | |
| Adipic Acid SCHEMBL6739298 | 0.89 | SLC1A1 (0.58) | SLC1A1GSRGRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836017-A | Organic long-acting fertilizer based on crosslinking, interpenetration and copolymerization and honeycomb fertilizer hiding process | 山东土秀才生物科技有限公司 | 2023-10-03 | — | — | CN | claimed |
| EP-4467143-B1 | METHOD FOR PREPARING 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12510533-B2 | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | CELGENE CORPORATION (US) | 2025-12-30 | — | — | US | disclosed |
| WO-2025096710-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4467143-A2 | 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE AS ANTIPROLIFERATIVE COMPOUND | Celgene Corporation (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240366593-A1 | ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE | SIGNAL PHARMACEUTICALS, LLC | 2024-11-07 | — | — | US | disclosed |
| US-20240366738-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | AGILENT TECHNOLOGIES INC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-3651766-B1 | 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE AS ANTIPROLIFERATIVE COMPOUND | CELGENE CORP (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-112399848-B | Antiproliferative compounds and bispecific antibodies against BCMA and CD3 for combined use | 细胞基因公司 | 2024-09-06 | — | — | CN | disclosed |
| US-12053466-B2 | Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use | CELGENE CORPORATION (US) | 2024-08-06 | — | — | US | disclosed |
| CN-1232395-A | Pharmaceutical compounds containing polyamines substituted with electron affinity groups | UNIV FLORIDA STATE (US) | 1999-10-20 | — | — | CN | disclosed |
| WO-1999020785-A1 | PRODUCTION OF GLUTAMATE USING WILD TYPE BACILLUS METHANOLICUS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0784629-B1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | DARWIN DISCOVERY LTD (GB) | 1999-04-28 | — | — | EP | disclosed |
| WO-1998014190-A9 | PHARMACEUTICAL COMPOUNDS COMPRISING POLYAMINES SUBSTITUTED WITH ELECTRON-AFFINIC GROUPS | — | 1998-07-30 | — | — | WO | disclosed |
| WO-1998014190-A1 | PHARMACEUTICAL COMPOUNDS COMPRISING POLYAMINES SUBSTITUTED WITH ELECTRON-AFFINIC GROUPS | FLORIDA STATE UNIVERSITY (US) | 1998-04-09 | — | — | WO | disclosed |
| WO-1994028012-A1 | HYDROXAMATE INHIBITORS OF ENDOTHELIN CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1994-12-08 | — | — | WO | disclosed |
| US-5338760-A | Urea derivatives, their preparation and medicinal products containing them | RHONE-POULENC RORER S.A. (FR) | 1994-08-16 | — | — | US | disclosed |
| EP-0443559-A2 | HIV protease inhibiting agents | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | disclosed |
| EP-0443573-A2 | HIV protease inhibitors containing derived amino acids | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | disclosed |
| US-4425280-A | POLYMER STABILIZERS | FERRO CORPORATION (US) | 1984-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366593-A1 | ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE | CD4, CD2, CD22 | SLC1A1 1037/4885GSR 4841/4885GRM8 1539/4885 |
| US-12510533-B2 | Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile | IKZF1, IKZF3, IKZF2 | SLC1A1 1299/4885GSR 4882/4885GRM8 4710/4885 |
| US-12053466-B2 | Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use | CD4, CD2, CD22 | SLC1A1 1037/4885GSR 4841/4885GRM8 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.